BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25587125)

  • 1. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
    Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
    Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
    Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
    Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.
    Vilhardt F; Nielsen M; Sandvig K; van Deurs B
    Mol Biol Cell; 1999 Jan; 10(1):179-95. PubMed ID: 9880335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
    Andres SA; Edwards AB; Wittliff JL
    J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
    Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
    Raij L; Tian R; Wong JS; He JC; Campbell KN
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D; Pöllänen J; Høyer-Hansen G; Rønne E; Sakaguchi K; Wun TC; Appella E; Danø K; Blasi F
    J Biol Chem; 1992 May; 267(13):9129-33. PubMed ID: 1315748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
    Li H; Kuo A; Kochan J; Strickland D; Kariko K; Barnathan ES; Cines DB
    J Biol Chem; 1994 Mar; 269(11):8153-8. PubMed ID: 7510679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells.
    Kenny S; Duval C; Sammut SJ; Steele I; Pritchard DM; Atherton JC; Argent RH; Dimaline R; Dockray GJ; Varro A
    Am J Physiol Gastrointest Liver Physiol; 2008 Sep; 295(3):G431-41. PubMed ID: 18599586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.
    Dal Monte M; Cammalleri M; Pecci V; Carmosino M; Procino G; Pini A; De Rosa M; Pavone V; Svelto M; Bagnoli P
    J Cell Mol Med; 2019 Feb; 23(2):1034-1049. PubMed ID: 30426662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.
    Bonavaud S; Charrière-Bertrand C; Rey C; Leibovitch MP; Pedersen N; Frisdal E; Planus E; Blasi F; Gherardi R; Barlovatz-Meimon G
    J Cell Sci; 1997 May; 110 ( Pt 9)():1083-9. PubMed ID: 9175704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes.
    Lang Y; Zhao Y; Zheng C; Lu Y; Wu J; Zhu X; Zhang M; Yang F; Xu X; Shi S; Liu Z
    Cell Death Dis; 2019 May; 10(6):401. PubMed ID: 31127093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1.
    Bhandary YP; Shetty SK; Marudamuthu AS; Ji HL; Neuenschwander PF; Boggaram V; Morris GF; Fu J; Idell S; Shetty S
    Am J Pathol; 2013 Jul; 183(1):131-43. PubMed ID: 23665346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
    Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
    Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.